ERBB2 and non-small cell lung carcinoma: Chemotherapy has been the cornerstone treatment for HER2-mutated NSCLC, with previous studies highlighting a median progression-free survival (mPFS) of 4.3 months for chemotherapy alone, 6.2 months for pemetrexed + platinum/bevacizumab, 2.6 months for gemcitabine, 4 months for paclitaxel + platinum/bevacizumab, and 3.5 months for vincristine.